US4983636A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition and method of treating selected malignant conditions
Assignee: RIKEN
•
Filing: 1988-10-31
•
Granted: 1991-01-08
•
Expires: 2008-10-31
Abstract
Abstract As a result of research work and investigations relating to the effect of benzaldehyde on cell membranes, it was found that benzaldehyde has high activity in the treatment of selected malignant conditions. Based on this finding, we have now completed the present invention directed to a composition comprising benzaldehyde as the active ingredient. This composition is effective against selected malignant conditions which are carcinoma of the colon, cancer of the stomach, cancer of the tongue, peritonitis carcinomatosa, cancer of the liver and malignancies induced by SF40 virus.
Inventors
- 👤 Setsuo Takeuchi
- 👤 Mutsuyuki Kochi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 18:45
CPC Classifications
B; B82; B82Y; B82Y5/00; A; A61; A61K; A61K31/00; A61K31/11; A61K47/00; A61K47/50; A61K47/69; A61K47/6949; A61K47/6951; A61P; A61P35/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
51 words
A composition, effective against a tumor selected from the group consisting of adenomatous carcinoma, leukaemia, squamous cell carcinoma, sarcoma and lymphosarcoma which comprises an inclusion compound of benzaldehyde in cyclodextrin as the active ingredient, wherein the inclusion compound contains 80 to 100 mg of benzaldehyde per gram of the inclusion compound.
Claim 2
Dependent Claim
51 words
A composition, effective against a tumor selected from the group consisting of adenomatous carcinoma, leukaemia, squamous cell carcinoma, sarcoma and lymphosarcoma which comprises an inclusion compound of benzaldehyde in cyclodextrin as the active ingredient, wherein the inclusion compound contains 80 to 100 mg of benzaldehyde per gram of the inclusion compound.
Claim 3
Dependent Claim
29 words
A composition according to claim 1 which is in the form of an enteric capsule which contains 50 to 200 mg of said inclusion compound of benzaldehyde in cyclodextrin.
Claim 4
Dependent Claim
29 words
A composition according to claim 1, wherein the in the form of an enteric tablet, which contains 50 to 200 mgs of said inclusion compound of benzaldehyde in cyclodextrin.
Claim 5
Dependent Claim
14 words
The composition according to claim 1, wherein the cyclodextrin is β or γ cyclodextrin.
Claim 6
Independent Claim
70 words
A method for treating a patient suffering from a tumor selected from the group consisting of adenamatous carcinoma, squamous cell carcinoma, sarcoma, leukaemia and lymphosarcoma, which comprises administering to said patient an amount sufficient to relieve said patient of a composition comprising benzaldehyde as the active ingredient in the form of a transfusion preparation or injection preparation containing 10 to 100 mg of benzaldehyde in 100 ml of the preparation.
Claim 7
Independent Claim
70 words
A method for treating a patient suffering from a tumor selected from the group consisting of adenamatous carcinoma, squamous cell carcinoma, sarcoma, leukaemia and lymphosarcoma, which comprises administering to said patient an amount sufficient to relieve said patient of a composition comprising benzaldehyde as the active ingredient in the form of a transfusion preparation or injection preparation containing 10 to 100 mg of benzaldehyde in 100 ml of the preparation.
Claim 8
Dependent Claim
21 words
The method according to claim 5, wherein the preparation is administered in an amount of 10 to 500 ml per day.
Claim 9
Dependent Claim
27 words
The method according to claim 5, wherein said composition is in water and is administered in the amount of 0.001-10 mg/kg of body weight once a day.
Claim 10
Independent Claim
60 words
A method for treating a patient suffering from a tumor selected from the group consisting of adenomatous carcinoma, squamous cell carcinoma, sarcoma, leukaemia and lymphosarcoma which comprises administering an amount sufficient to relieve said patient of a composition comprising benzaldehyde as the active ingredient in the form of a capsule containing 5 to 50 mg of benzaldehyde to said patient.
Claim 11
Independent Claim
60 words
A method for treating a patient suffering from a tumor selected from the group consisting of adenomatous carcinoma, squamous cell carcinoma, sarcoma, leukaemia and lymphosarcoma which comprises administering an amount sufficient to relieve said patient of a composition comprising benzaldehyde as the active ingredient in the form of a capsule containing 5 to 50 mg of benzaldehyde to said patient.
Claim 12
Dependent Claim
26 words
The method according to claim 8, wherein the composition is administered in an amount of 1 to 10 capsules and 1 to 10 times per day.
Claim 13
Dependent Claim
23 words
The method according to claim 8, wherein the composition is administered orally in the amount of 0.005-50 mg/kg of body weight per day.
Claim 14
Independent Claim
53 words
A method for treating a patient suffering from a tumor selected from the group consisting of adenomatous carcinoma, squamous cell carcinoma, sarcoma, leukaemia and lymphosarcoma which comprises administering an amount sufficient to relieve said patient of a composition comprising an inclusion compound of benzaldehyde in cyclodextrin as the active ingredient to said patient.
Claim 15
Independent Claim
53 words
A method for treating a patient suffering from a tumor selected from the group consisting of adenomatous carcinoma, squamous cell carcinoma, sarcoma, leukaemia and lymphosarcoma which comprises administering an amount sufficient to relieve said patient of a composition comprising an inclusion compound of benzaldehyde in cyclodextrin as the active ingredient to said patient.
Claim 16
Dependent Claim
31 words
The method according to claim 11, wherein the inclusion compound of benzaldehyde in cyclodextrin is administered in an amount of 0.5 to 15 g and 1 to 10 times per day.
Claim 17
Dependent Claim
37 words
The method according to claim 11, wherein the administering said composition in the form of an enteric capsule or enteric tablet containing 50 to 200 mg of said inclusion compound of benzaldehyde in cyclodextrin to said patient.
Claim 18
Dependent Claim
25 words
The method according to claim 13, wherein the composition is administered in an amount of 1 to 10 capsules 1 to 10 times per day.
References Cited (Backward Citations)
US2827452A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-07 | 1994-07-09 | 1995-01-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-07 | 1998-07-09 | 1999-01-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-07 | 2002-07-09 | 2003-01-08 | $7700.00 | Window Closed / Lapsed |